Debra Silberg
Direktor/Vorstandsmitglied bei Ellodi Pharmaceuticals
Aktive Positionen von Debra Silberg
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Ellodi Pharmaceuticals
 Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | Direktor/Vorstandsmitglied | 27.02.2023 | - |
Karriereverlauf von Debra Silberg
Ehemalige bekannte Positionen von Debra Silberg
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Technik-/Wissenschafts-/F&E-Leiter | 10.11.2021 | - |
| SHIRE | Corporate Officer/Principal | 01.04.2015 | - |
Ausbildung von Debra Silberg
| University of Michigan | Undergraduate Degree |
| D'Amore-Mckim School of Business | Doctorate Degree |
| The Wayne State University School of Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
| Irland | 2 |
Operativ
| Doctorate Degree | 2 |
| Corporate Officer/Principal | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Consumer Services | 4 |
| Health Technology | 3 |
| Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Private Unternehmen | 2 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Ellodi Pharmaceuticals
Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | Health Technology |
- Börse
- Insiders
- Debra Silberg
- Erfahrung